Trial Profile
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2022
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Degarelix (Primary) ; Indometacin (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 07 Jan 2021 Status changed from active, no longer recruiting to completed.
- 11 Sep 2020 Planned End Date changed from 10 Sep 2020 to 31 Dec 2020.
- 08 Jan 2020 Planned End Date changed from 10 Dec 2020 to 10 Sep 2020.